CSBIO(SZ:300255)2014-03-31 16:00Financial Performance - The company's operating revenue for 2013 was CNY 704,542,401.29, representing a 22.41% increase compared to CNY 575,558,108.32 in 2012[18]. - The net profit attributable to shareholders for 2013 was CNY 115,182,918.60, which is a 16.24% increase from CNY 99,088,101.11 in the previous year[18]. - The total assets at the end of 2013 amounted to CNY 1,645,301,155.03, reflecting a 15.99% increase from CNY 1,418,450,309.50 in 2012[18]. - The company's total liabilities increased by 22.89% to CNY 359,778,251.96 in 2013, up from CNY 292,772,984.09 in 2012[18]. - The weighted average return on equity for 2013 was 9.95%, slightly up from 9.56% in 2012[18]. - The basic earnings per share for 2013 was CNY 0.61, an increase of 12.96% from CNY 0.54 in 2012[18]. - The net profit after deducting non-recurring gains and losses was CNY 113,151,213.33, a 19.89% increase from CNY 94,377,599.46 in 2012[18]. - The total equity attributable to shareholders increased by 11.79% to CNY 1,229,321,083.12 at the end of 2013, compared to CNY 1,099,631,042.67 in 2012[18]. - The company achieved a net profit attributable to shareholders of 115,182,918.60 CNY in 2013, representing a 16.24% increase compared to the previous year[30]. - Total operating revenue for 2013 was 704,542,400 CNY, reflecting a growth of 22.41% year-over-year[30]. Sales and Revenue Breakdown - The sales revenue from low molecular weight heparin calcium injection reached 428,092,100 CNY, a significant increase of 47.81% compared to the previous year, with sales volume growing by 37.22%[30]. - The company’s heparin sodium raw material sales revenue declined to 217,504,000 CNY, a decrease of 14.77% year-over-year, with sales volume down by 10.66%[30]. - The company’s revenue from low molecular weight heparin injection reached CNY 428,092,116.27, with a gross margin of 80.31%, reflecting a 47.81% increase in revenue year-over-year[51]. - The company’s revenue from domestic sales was CNY 532,668,069.43, with a gross margin of 70.8%, while international sales amounted to CNY 171,137,818.62, with a gross margin of 9.87%[50]. Research and Development - Research and development investment increased by CNY 23.97 million in 2013, with capitalized R&D expenses amounting to CNY 17.06 million[41]. - The company is in the experimental research phase for several new products, including ultra-low molecular heparin sodium and heparin sodium for deep vein thrombosis prevention, aiming to obtain drug registration certificates[42]. - The company is actively involved in the research and development of new pharmaceutical products, including non-medical nutritional products and medical dressings[58]. - The company plans to accelerate the registration and research of new drugs, including the heparin series and drugs for diabetes and tumors, to enhance its product portfolio[79]. Market Strategy and Expansion - The company aims to enhance its marketing, research, production, and management capabilities to address intensified market competition in the heparin raw material sector[26]. - The company plans to expand its market presence and invest in new product development to drive future growth[186]. - The company is focusing on expanding its business and developing new products, particularly in the heparin market[94]. - The company aims to achieve drug registration for multiple products currently in the experimental stage, including sodium heparin and skin sulfate raw materials[42]. Financial Management and Investments - The company reported a significant increase in sales expenses, which rose by 37.99% to CNY 158.67 million, primarily due to increased promotional costs and employee compensation[41]. - The cash flow from operating activities showed a significant improvement, with a net cash flow of CNY -15,244,396.02 in 2013, compared to CNY -70,620,873.55 in 2012, marking a 78.41% improvement[18]. - The company’s cash flow from financing activities decreased by 92.60% to CNY 4,518,199.36, primarily due to reduced equity incentive payments compared to the previous year[45]. - The company utilized RMB 98.443 million of raised funds to replace self-raised funds for investment projects[71]. Corporate Governance and Compliance - The company has established and strictly executed an insider information management system to protect investor rights[91]. - The company engaged in multiple investor communications, discussing topics such as market expansion and product development plans[94]. - The governance structure complies with relevant laws and regulations, ensuring independent operation of the board and supervisory committee[157]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors[164]. Shareholder Information - The total number of shareholders at the end of the reporting period was 4,307, compared to 5,033 five trading days before the report date[126]. - The largest shareholder, Gao Shuhua, holds 31.83% of the shares, totaling 59,976,000 shares[126]. - The company has a cash dividend policy that remains unchanged, with no cash dividends distributed in 2013[85]. - The company will not distribute profits for 2013, opting to reinvest for future growth and expansion[87].